C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter A—GeneralPart 10—Administrative Practices and ProceduresSubpart B—General Administrative Procedures

21 C.F.R. § 10.85 (2026)

Advisory opinions

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1980–2024 32citing cases
At a glance

Courts have cited this section in 32 opinions since 1980, 3 of them in the last five years.

(a) An interested person may request an advisory opinion from the Commissioner on a matter of general applicability.

(1) The request will be granted whenever feasible.

(2) The request may be denied if:

(i) The request contains incomplete information on which to base an informed advisory opinion;

(ii) The Commissioner concludes that an advisory opinion cannot reasonably be given on the matter involved;

(iii) The matter is adequately covered by a prior advisory opinion or a regulation;

(iv) The request covers a particular product or ingredient or label and does not raise a policy issue of broad applicability; or

(v) The Commissioner otherwise concludes that an advisory opinion would not be in the public interest.

(b) A request for an advisory opinion is to be submitted in accordance with § 10.20, is subject to the provisions of § 10.30 (c) through (l), and must be in the following form:

(Date)

Dockets Management Staff, Food and Drug Administration, Department of Health and Human Services, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Request for Advisory Opinion

The undersigned submits this request for an advisory opinion of the Commissioner of Food and Drugs with respect to ______ (the general nature of the matter involved).

A. Issues involved.

(A concise statement of the issues and questions on which an opinion is requested.)

B. Statement of facts and law.

(A full statement of all facts and legal points relevant to the request.)

The undersigned certifies that, to the best of his/her knowledge and belief, this request includes all data, information, and views relevant to the matter, whether favorable or unfavorable to the position of the undersigned, which is the subject of the request.

(Signature) (Person making request) (Mailing address) (Telephone number)

(c) The Commissioner may respond to an oral or written request to the agency as a request for an advisory opinion, in which case the request will be filed with the Dockets Management Staff and be subject to this section.

(d) A statement of policy or interpretation made in the following documents, unless subsequently repudiated by the agency or overruled by a court, will constitute an advisory opinion:

(1) Any portion of a Federal Register notice other than the text of a proposed or final regulation, e.g., a notice to manufacturers or a preamble to a proposed or final regulation.

(2) Trade Correspondence (T.C. Nos. 1-431 and 1A-8A) issued by FDA between 1938 and 1946.

(3) Compliance policy guides issued by FDA beginning in 1968 and codified in the Compliance Policy Guides manual.

(4) Other documents specifically identified as advisory opinions, e.g., advisory opinions on the performance standard for diagnostic X-ray systems, issued before July 1, 1975, and filed in a permanent public file for prior advisory opinions maintained by the Division of Freedom of Information (ELEM-1029)” and adding in its place “(the Freedom of Information Staff's address is available on the agency's web site at http://www.fda.gov.)

(e) An advisory opinion represents the formal position of FDA on a matter and except as provided in paragraph (f) of this section, obligates the agency to follow it until it is amended or revoked. The Commissioner may not recommend legal action against a person or product with respect to an action taken in conformity with an advisory opinion which has not been amended or revoked.

(f) In unusual situations involving an immediate and significant danger to health, the Commissioner may take appropriate civil enforcement action contrary to an advisory opinion before amending or revoking the opinion. This action may be taken only with the approval of the Commissioner, who may not delegate this function. Appropriate amendment or revocation of the advisory opinion involved will be expedited.

(g) An advisory opinion may be amended or revoked at any time after it has been issued. Notice of amendment or revocation will be given in the same manner as notice of the advisory opinion was originally given or in the Federal Register, and will be placed on public display as part of the file on the matter in the office of the Dockets Management Staff. The Dockets Management Staff shall maintain a separate chronological index of all advisory opinions filed. The index will specify the date of the request for the advisory opinion, the date of the opinion, and identification of the appropriate file.

(h) Action undertaken or completed in conformity with an advisory opinion which has subsequently been amended or revoked is acceptable to FDA unless the Commissioner determines that substantial public interest considerations preclude continued acceptance. Whenever possible, an amended or revoked advisory opinion will state when action previously undertaken or completed does not remain acceptable, and any transition period that may be applicable.

(i) An interested person may submit written comments on an advisory opinion or modified advisory opinion. Four copies of any comments are to be sent to the Dockets Management Staff for inclusion in the public file on the advisory opinion. Individuals may submit only one copy. Comments will be considered in determining whether further modification of an advisory opinion is warranted.

(j) An advisory opinion may be used in administrative or court proceedings to illustrate acceptable and unacceptable procedures or standards, but not as a legal requirement.

(k) A statement made or advice provided by an FDA employee constitutes an advisory opinion only if it is issued in writing under this section. A statement or advice given by an FDA employee orally, or given in writing but not under this section or § 10.90, is an informal communication that represents the best judgment of that employee at that time but does not constitute an advisory opinion, does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

[44 FR 22323, Apr. 13, 1979, as amended at 46 FR 8455, Jan. 27, 1981; 59 FR 14364, Mar. 28, 1994; 65 FR 56477, Sept. 19, 2000; 76 FR 31469, June 1, 2011; 79 FR 68114, Nov. 14, 2014]
The 20 cases that cite 21 C.F.R. § 10.85 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENKoenig v. Boulder Brands, Inc., 995 F. Supp. 2d 274 (S.D.N.Y. 2014).
cites § 10.85 4×cited by 84 cases
Where it cites § 10.85
“21 C.F.R. § 10.85 . The regulations explicitly state that certain statements of policy or interpretation, including statements known as Compliance Policy Guides, constitute advisory opinions.”
The case’s holding
A consumer establishes a claim for deceptive practices by alleging they would not have purchased a product at its advertised price had the true ingredients been disclosed.
Later courts cite it for
“to state a claim for unjust enrichment under new york law, a plaintiff must allege that '(1) the defendant was enriched, (2) at the expense of the plaintiff, and (3) . . . it would be inequitable to permit the defendant to retain that which is claimed by the plaintiff.” · 8 citing courts
2
GREENDoe v. Rumsfeld, 297 F. Supp. 2d 119 (D.D.C. 2003).
cites § 10.85 2×cited by 23 cases
The case’s holding
Judicial review of a military order to submit to anthrax vaccination is permissible where the order came from the Secretary of Defense rather than from commanders in the field.
Later courts cite it for
“military authority exercised in the field in a time of war or in occupied territory” · 2 citing courts
3
GREENIn re Zyprexa Prods. Liab. Litig., 489 F. Supp. 2d 230 (E.D.N.Y. 2007).
cites § 10.85 1×cited by 94 cases
Where it cites § 10.85
“See 21 C.F.R. § 10.85 (d)(1), (e), (g). The Supreme Court has ruled that internal agency guidelines which are not promulgated subject to notice and comment procedures are entitled only to "some deference.”
The case’s holding
Expert testimony is not excluded solely because a witness lacks specialized expertise if they possess qualifications in a general field closely related to the subject matter.
Later courts cite it for
“if the expert has educational and experiential qualifications in a general field closely related to the subject matter in question, the court will not exclude the testimony solely on the ground that the witness lacks expertise in the specialized areas that are directly pertinent.” · 5 citing courts
4
cites § 10.85 1×cited by 76 cases
The case’s holding
Informal and advisory agency warning letters that do not compel action by the recipient or the agency do not constitute final agency action subject to judicial review.
Later courts cite it for
“must assume that the plaintiff states a valid legal claim and must accept the factual allegations in the complaint as true,” · 6 citing courts
5
GREENColacicco v. Apotex, Inc., 432 F. Supp. 2d 514 (E.D. Pa. 2006).
cites § 10.85 1×cited by 52 cases
Where it cites § 10.85
“" 21 C.F.R. § 10.85 (j) (emphasis added). Because by all accounts the preamble lacks the force and effect of law, we agree with Defendants that an effective date analysis would accordingly be irrelevant.”
The case’s holding
State tort claims against generic drug manufacturers for failure to warn are preempted when federal law requires labeling to be identical to the brand-name drug label.
Later courts cite it for
“state tort law which would hold a generic drug manufacturer liable for failing to modify a label when, pursuant to the hatch-waxman amendments to the fdca food, drug, and cosmetic act, the anda approval process required that the labeling be the same as that approved for the innovator drug, and when the fda would have deemed any post-approval enhancements 'false or misleading,' would actually conflict with the fdca” · 2 citing courts
6
GREENKnipe v. SmithKline Beecham, 583 F. Supp. 2d 553 (E.D. Pa. 2008).
cites § 10.85 1×cited by 36 cases
Where it cites § 10.85
“See 21 C.F.R. § 10.85 (d)(1), (e), (g). “[F]ederal law capable of preempting is [not] created every time someone acting on behalf of an agency makes a statement or takes an action within the agency’s jurisdiction.”
The case’s holding
State law failure-to-warn claims are not preempted by federal law unless a direct conflict exists making it impossible to comply with both state and federal requirements.
Later courts cite it for
“motions for reconsideration may not be used 'as a means to argue new facts or issues that inexcusably were not presented to the court in the matter previously decided.” · 8 citing courts
7
GREENLockwood v. Conagra Foods, Inc., 597 F. Supp. 2d 1028 (N.D. Cal. 2009).
cites § 10.85 1×cited by 29 cases
Where it cites § 10.85
“21 C.F.R. § 10.85 (d), (e). The policy, however, does not establish a legal requirement.”
The case’s holding
Consumer-protection claims challenging a food's labeling as misleading are not preempted by federal food-labeling law where the labeling falls outside federally regulated areas, since courts can decide whether conduct is misleading.
Later courts cite it for
“gives the fda the responsibility to protect the public health by ensuring that 'foods are safe, wholesome, sanitary, and properly labeled.” · 5 citing courts
8
GREENPelayo v. Nestle USA, Inc., 989 F. Supp. 2d 973 (C.D. Cal. 2013).
cites § 10.85 1×cited by 27 cases
Where it cites § 10.85
“July 23, 2010); see also 21 C.F.R. § 10.85 (d), (e), and (j). Ultimately, the FDA and Federal Trade Commission (“FTC”) declined to adopt a definition of “natural” because “natural may be used in numerous contexts and may convey different meanings depending on that context.”
The case’s holding
A court may dismiss false labeling claims without leave to amend where it concludes as a matter of law that the product packaging is not likely to deceive reasonable consumers.
Later courts cite it for
“where a court can conclude as a matter of law that members of the public are not likely to be deceived by the product packaging, dismissal is appropriate.” · 4 citing courts
9
GREENWeiss v. Fujisawa Pharm. Co., 464 F. Supp. 2d 666 (E.D. Ky. 2006).
cites § 10.85 2×cited by 8 cases
Where it cites § 10.85
“Even though it represents FDA’s formal position on a matter and obligates the agency to follow it until amended or revoked, 21 C.F.R. § 10.85 (g), an advisory opinion is also entitled only to limited deference because it is not subject to notice and comment procedures.”
10
GREENElena Nacarino v. Kashi Co., 77 F.4th 1201 (9th Cir. 2023).
cites § 10.85 1×cited by 9 cases
Where it cites § 10.85
“Unlike the Federal Register memo and the FAQ website, the agency’s regulations disclaim that such statements reflect the FDA’s official position or “otherwise obligate or commit the agency to the views expressed.”
Later courts cite it for
“the 20 fdca expressly preempts all state statutes and law that 'directly or indirectly establish 21 any requirement for the labeling of food that is not identical to the federal requirements' 22 set forth by statute and food and drug administration (fda) regulations.” · 2 citing courts
11
GREENDePriest v. Astrazeneca Pharm., L.P., 2009 Ark. 547, 351 S.W.3d 168.
cites § 10.85 1×cited by 22 cases
Where it cites § 10.85
“21 C.F.R. § 10.85 (k) (2009). 12 . The original claim that AstraZeneca engaged in price fixing was rejected by the trial court and is not pursued on appeal.”
12
GREENUnited States v. Facteau, 89 F.4th 1 (1st Cir. 2023).
cites § 10.85 1×cited by 8 cases
Where it cites § 10.85
“The letter did not offer an advisory opinion under 21 C.F.R. § 10.85 , and it was therefore an "informal communication" that "[did] not necessarily represent the formal position of FDA, and [did] not bind or otherwise obligate or commit the agency to the views expressed.”
Later courts cite it for
“make apparent his theory of the district court's plain error, and he did squarely address the plain error factors in his reply brief,” · 1 citing court
13
GREENBracco Diagnostics, Inc. v. Shalala, 963 F. Supp. 20 (D.D.C. 1997).
cites § 10.85 1×cited by 47 cases
Where it cites § 10.85
“In its preamble, which constitutes an advisory opinion binding on the agency unless repudiated by the agency, see 21 C.F.R. § 10.85 (d)(1), (e), the FDA stated: “The agency has determined that all radiologic contrast media, including barium enema kits, are to be regulated by FDA…”
The case’s holding
An agency acts arbitrarily and capriciously when it treats functionally indistinguishable products differently without providing a legitimate reason for the disparate treatment.
Later courts cite it for
“while the injury to plaintiffs is admittedly economic, there is no adequate compensatory or other corrective relief that can be provided at a later date, tipping the balance in favor of injunctive relief.” · 5 citing courts
14
GREENPerry v. Novartis Pharma. Corp., 456 F. Supp. 2d 678 (E.D. Pa. 2006).
cites § 10.85 1×cited by 19 cases
Where it cites § 10.85
“See 21 C.F.R. § 10.85 (d)(1) (identifying as an advisory opinion “[a]ny portion of a Federal Register notice other than the text of a proposed or final regulation, e.”
Later courts cite it for
“where, however, the fda has made a conclusive determination, positive or negative, as to the existence of a link between the drug at issue and some adverse health consequence, state law cannot mandate that a manufacturer include additional warning beyond those that the fda has determine to be appropriate to the risk.” · 2 citing courts
15
cites § 10.85 1×cited by 41 cases
The case’s holding
An agency policy delineating factors for determining whether to bring an enforcement action does not constitute a substantive rule requiring notice and comment.
Later courts cite it for
“what purpose would an agency's statement of policy serve if agency employees could not refer to it for guidance?” · 3 citing courts
cites § 10.85 1×cited by 7 cases
Where it cites § 10.85
“” See 21 C.F.R. § 10.85 (k). Nevertheless, like the Fourth Circuit in Brown & Williamson, the court finds these statements to be illuminating.”
17
GREENSe. Minerals, Inc. v. Patricia Roberts Harris, 622 F.2d 758 (5th Cir. 1980).
cites § 10.85 1×cited by 12 cases
Where it cites § 10.85
“See generally 21 C.F.R. §§ 10.85 (c), (d)(3) (1978). There, the FDA stated that “[tjhere is no food additive regulation providing for the safe use of gentian violet in animal feed, nor is there prior sanction for its use.”
18
GREENSchering-Plough Healthcare Prods., Inc. v. Schwarz Pharma, Inc., 547 F. Supp. 2d 939 (E.D. Wis. 2008).
cites § 10.85 1×cited by 6 cases
Where it cites § 10.85
“is an informal communication that represents the best judgment of that employee at that time but does not constitute an advisory opinion, does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views…”
19
GREENUnited States v. Regenerative Sciences, LLC, 878 F. Supp. 2d 248 (D.D.C. 2012).
cites § 10.85 1×cited by 6 cases
Where it cites § 10.85
“See 21 C.F.R. § 10.85 (d)(1) & (j) (stating that a preamble constitutes an advisory opinion and may be used for illustrative purposes but “not as a legal requirement”).”
Later courts cite it for
“to constitute final agency action, two conditions must be met: (1) 'the action must mark the consummation of the agency's decisionmaking process' and (2) it 'must be one by which rights or obligations have been determined, or from which legal consequences will flow.” · 2 citing courts
20
GREENKellogg v. Wyeth, 612 F. Supp. 2d 421 (D. Vt. 2008).
cites § 10.85 1×cited by 5 cases
Where it cites § 10.85
“See 21 C.F.R. § 10.85 (d)(1) (a statement of policy or interpretation other than the text of a proposed or final regulation constitutes an advisory opinion).”

Show all 32 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198020022024

One bar per year. Tallest: 4 cases in 2008. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.7E.D. Pa.35th Cir.29th Cir.2D.N.J.2E.D.N.Y2Ark.11st Cir.1

The 8 courts with the most citing cases, of 20 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 32 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com